Evaluation of a Methotrexate Chemiluminescent Microparticle Immunoassay Comparison to Fluorescence Polarization Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry

被引:20
作者
Bouquie, Regis [1 ]
Gregoire, Matthieu [1 ]
Hernando, Helene [1 ]
Azoulay, Claudine [1 ]
Dailly, Eric [1 ]
Monteil-Ganiere, Catherine [1 ]
Pineau, Alain [1 ]
Deslandes, Guillaume [1 ]
Jolliet, Pascale [1 ]
机构
[1] CHU Nantes, Dept Clin Pharmacol, Nantes, France
关键词
Methotrexate; CMIA; FPIA; Mass spectrometry; Therapeutic drug monitoring; Cancer; NEPHROTOXICITY;
D O I
10.1093/ajcp/aqw088
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: For most laboratories, methotrexate (MTX) concentrations are routinely monitored by fluorescence polarization immunoassay (FPIA). In anticipation of an announced withdrawal of the FPIA reagent on the Abbott TDxFLx (Abbott Diagnostics, Abbott Park, IL), we have evaluated a new reagent kit developed by Abbott on the Architect i1000, based on chemiluminescent microparticle immunoassay (CMIA). Methods: Precision, inaccuracy, and selectivity were assessed. Interassay variability was established using 75 plasma patient samples treated with MTX and analyzed by two methods: FPIA and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: For MTX, the intraday inaccuracy was between 6.37% and + 3.52%, while interday performance was between -3.70% and 7.90%. Intraday and interday imprecision was less than 2.65% and less than 2.22%, respectively. The correlation coefficient between CMIA and FPIA or LCMS/MS was 0.9969 and 0.9985, respectively. Conclusions: These results comparing CMIA vs FPIA and LC-MS/MS indicate that CMIA is a suitable alternative to the FPIA method.
引用
收藏
页码:119 / 124
页数:6
相关论文
共 16 条
[1]   Difficulty Measuring Methotrexate in a Patient with High-Dose Methotrexate-Induced Nephrotoxicity [J].
Al-Turkmani, M. Rabie ;
Law, Terence ;
Narla, Anupama ;
Kellogg, Mark D. .
CLINICAL CHEMISTRY, 2010, 56 (12) :1792-1794
[2]  
[Anonymous], 2013, FDA UPDATES BIOANALY
[3]   Improved Sensitivity for Methotrexate Analysis Using Enzyme Multiplied Immunoassay Technique on the Siemens Viva-E Instrument [J].
Borgman, Mark P. ;
Hiemer, Mary F. ;
Molinelli, Alejandro R. ;
Ritchie, James C. ;
Jortani, Saeed A. .
THERAPEUTIC DRUG MONITORING, 2012, 34 (02) :193-197
[4]   COMPARATIVE-STUDY ON THE PHARMACOKINETICS OF 7-HYDROXY-METHOTREXATE AFTER ADMINISTRATION OF METHOTREXATE IN THE DOSE RANGE OF 0.5-33.6 G/M2 TO CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
BORSI, JD ;
SAGEN, E ;
ROMSLO, I ;
MOE, PJ .
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (03) :217-224
[5]   A fast LC-MS/MS assay for methotrexate monitoring in plasma: validation, comparison to FPIA and application in the setting of carboxypeptidase therapy [J].
Bouquie, Regis ;
Deslandes, Guillaume ;
Bernaldez, Blanca Nieto ;
Renaud, Christian ;
Dailly, Eric ;
Jolliet, Pascale .
ANALYTICAL METHODS, 2014, 6 (01) :178-186
[6]   Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients [J].
Christensen, Anthony M. ;
Pauley, Jennifer L. ;
Molinelli, Alejandro R. ;
Panetta, John C. ;
Ward, Deborah A. ;
Stewart, Clinton F. ;
Hoffman, James M. ;
Howard, Scott C. ;
Pui, Ching-Hon ;
Pappo, Alberto S. ;
Relling, Mary V. ;
Crews, Kristine R. .
CANCER, 2012, 118 (17) :4321-4330
[7]  
Cofrac-Comitefrancais d'accreditation, 2014, SH REF 08 GUID TECHN
[8]   Multicenter method evaluation of the ARK™ Methotrexate Immunoassay [J].
Godefroid, Maaike J. G. ;
von Meyer, Alexander ;
Parsch, Hans ;
Streichert, Thomas ;
Verstraete, Alain G. ;
Stove, Veronique .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (02) :E13-E16
[9]   THE CELLULAR PHARMACOLOGY OF METHOTREXATE [J].
GOLDMAN, ID ;
MATHERLY, LH .
PHARMACOLOGY & THERAPEUTICS, 1985, 28 (01) :77-102
[10]   Unexpected Overestimation of Methotrexate Plasma Concentrations: Analysis of a Single Center Pediatric Population [J].
Guerriero, Emilie ;
Simon, Nicolas ;
Nelken, Brigitte ;
Baldeyrou, Brigitte ;
Djobo, Bodale ;
Vasseur, Michele ;
Allorge, Delphine ;
Decaudin, Bertrand ;
Odou, Pascal .
THERAPEUTIC DRUG MONITORING, 2014, 36 (04) :499-504